Literature DB >> 3277539

The insulinomimetic effects of the polar head group of an insulin-sensitive glycophospholipid on pyruvate dehydrogenase in both subcellular and whole cell assays.

W K Gottschalk1, L Jarett.   

Abstract

The polar head group that was released by treating an insulin-sensitive glycophospholipid with a phosphatidylinositol-specific phospholipase C (PI-PLC) stimulated pyruvate dehydrogenase (PDH) in both subcellular and whole cell assays. Stimulation of PDH activity in the subcellular assay was detected after gel filtration chromatography of the polar head group. This stimulation was not due to the presence of contaminating calcium and magnesium. The PDH-stimulating activity was proportional to the amount of polar head group added to the assay. The effect of the polar head group on PDH in the subcellular assay was blocked by sodium fluoride, suggesting that the polar head group activated the PDH phosphatase. In the whole cell assay, the polar head group stimulated PDH activity to an equal or greater extent as a physiological concentration of insulin. The effect of the polar head group was detected at 5 min, peaked at 10 min, and declined thereafter. In contrast, insulin stimulated PDH activity more slowly, but consistently. The PDH-stimulating activity eluted after bacitracin but ahead of ATP during gel filtration chromatography, and it was destroyed by exposure to NH4OH or alkaline phosphatase and by boiling in water. These data support the proposal that an early step in insulin action is the release of insulinomimetic polar head group from the insulin-sensitive glycophospholipid.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3277539     DOI: 10.1016/0003-9861(88)90116-6

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  8 in total

1.  Transport in isolated rat hepatocytes of the phospho-oligosaccharide that mimics insulin action. Effects of adrenalectomy and glucocorticoid treatment.

Authors:  J F Alvarez; J A Sánchez-Arias; A Guadaño; F Estévez; I Varela; J E Felíu; J M Mato
Journal:  Biochem J       Date:  1991-03-01       Impact factor: 3.857

2.  Molecular effects of sulphonylurea agents in circulating lymphocytes of patients with non-insulin-dependent diabetes mellitus.

Authors:  I Rabbone; M Piccinini; M Curto; M Mostert; S Gamba; S Mioletti; R Bruno; M T Rinaudo
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

3.  Derangements of pyruvate dehydrogenase in circulating lymphocytes of NIDDM patients and their healthy offspring.

Authors:  M Mostert; I Rabbone; M Piccinini; M Curto; S Vai; A Musso; M T Rinaudo
Journal:  J Endocrinol Invest       Date:  1999 Jul-Aug       Impact factor: 4.256

4.  The endogenous cyclic AMP antagonist, cyclic PIP: its ubiquity, hormone-stimulated synthesis and identification as prostaglandylinositol cyclic phosphate.

Authors:  H K Wasner; U Salge; M Gebel
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

Review 5.  The role of glycosyl-phosphoinositides in hormone action.

Authors:  A R Saltiel
Journal:  J Bioenerg Biomembr       Date:  1991-02       Impact factor: 2.945

6.  Growth hormone inhibits activation of phosphatidylinositol phospholipase C in adipose plasma membranes: evidence for a growth hormone-induced change in G protein function.

Authors:  P Roupas; S Y Chou; R J Towns; J L Kostyo
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

7.  Cell-based regenerative strategies for treatment of diabetic skin wounds, a comparative study between human umbilical cord blood-mononuclear cells and calves' blood haemodialysate.

Authors:  Hala O El-Mesallamy; Mohamed R Diab; Nadia M Hamdy; Sarah M Dardir
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

8.  Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.

Authors:  Dan Ziegler; Lusine Movsesyan; Boris Mankovsky; Irina Gurieva; Zhangentkhan Abylaiuly; Igor Strokov
Journal:  Diabetes Care       Date:  2009-05-26       Impact factor: 17.152

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.